Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo shows promise in HER2-positive breast cancer with brain mets

Publish date:: March 15, 2019

Key clinical point: Combination neratinib and capecitabine showed favorable efficacy outcomes, but also high toxicity, in patients with HER2-positive breast cancer and brain metastases.

Major finding: The median progression-free survival was 5.5 and 3.1 months in two separate patient cohorts.

Study details: A phase 2 study of 49 patients with HER2-positive breast cancer and brain metastases.

Disclosures: The study was supported by grant funding from Puma Biotechnology, the Translational Breast Cancer Research Consortium’s foundation partners, the American Cancer Society, Susan G. Komen for the Cure, the Breast Cancer Research Foundation, and the Dana-Farber/Harvard Cancer Center. The authors reported financial affiliations with Puma Biotechnology, Genentech, Eli Lilly, Novartis, Pfizer, and others.

Citation:

Freedman RA et al. J Clin Oncol. 2019 Mar 12. doi: 10.1200/JCO.18.01511.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,